S
Sarepta Therapeutics, Inc. (SRPT)
NMS – Real Time Price. Currency in USD
19.97
-1.71 (-7.89%)
At close: Mar 27, 2026, 4:00 PM EDT
20.04
+0.07 (0.35%)
After-hours: Mar 27, 2026, 7:32 PM EDT
Get all premium features to the best stock analysis tool
NMS – Real Time Price. Currency in USD
19.97
-1.71 (-7.89%)
At close: Mar 27, 2026, 4:00 PM EDT
20.04
+0.07 (0.35%)
After-hours: Mar 27, 2026, 7:32 PM EDT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children’s Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
| Name | Position |
|---|---|
| Dr. Diane L. Berry Ph.D. | Executive VP and Chief of Global Policy & Advocacy Officer |
| Dr. Louise R. Rodino-Klapac Ph.D. | President of Research & Development and Technical Operations |
| Mr. Douglas S. Ingram Esq., J.D. | CEO & Director |
| Mr. Ian Michael Estepan | President & COO |
| Ms. Alison Nasisi | Executive VP & Chief People Officer |
| Ms. Cristin L. Rothfuss J.D. | Executive Vice President, General Counsel & Company Secretary |
| Patrick Moss Pharm.D. | Executive VP & Chief Commercial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-03-02 | 10-K | srpt-20251231.htm |
| 2026-01-12 | 8-K | srpt-20260112.htm |
| 2025-12-19 | 8-K | d32354d8k.htm |
| 2025-12-11 | 8-K | d55628d8k.htm |
| 2025-12-08 | 8-K | d15497d8k.htm |
| 2025-11-06 | 10-Q | srpt-20250930.htm |
| 2025-11-03 | 8-K | srpt-20251103.htm |
| 2025-08-29 | 8-K | d945054d8k.htm |
| 2025-08-21 | 8-K | d938350d8k.htm |
| 2025-08-13 | 8-K | d59666d8k.htm |
| Rachael Potter Ph.D. | Chief Scientific Officer |
| Ryan H. Wong | Executive VP & CFO |
| Tamara Thornton | Director of Finance, Treasury & Investor Relations |